Aurobindo Pharma Limited has announced its financial results for the fourth quarter and full financial year ended March 31, 2026. The company reported a consolidated revenue of ₹8,853 crore, marking a 5.6% year-on-year growth. This performance was driven by strong results in the European market and stable operations in the US, despite lower transient product sales. Net profit for the quarter rose to ₹921 crore, representing a 2.0% increase compared to the same period last year.
Financial Performance Overview
For Q4 FY26, Aurobindo Pharma achieved a revenue of ₹8,853 crore, up 5.6% from ₹8,382 crore in Q4 FY25. EBITDA for the quarter stood at ₹1,801 crore, reflecting a margin of 20.3%, supported by stable gross margins and operational efficiencies. Net profit reached ₹921 crore, compared to ₹903 crore in the previous year, demonstrating resilient growth.
Geographic and Segment Highlights
The US formulations business generated US$ 387 million in revenue, accounting for 40.0% of the total consolidated revenue. While the base business remained stable, the quarter saw 12 product launches and 9 ANDA approvals. The Europe segment emerged as a key growth driver, posting a 30.2% year-on-year revenue increase to ₹2,795 crore. Additionally, the API business recorded a 12.9% year-on-year growth, reaching ₹1,208 crore, largely fueled by volume expansion in the non-antibiotics segment.
Strategic Progress in Biosimilars
The company continues to advance its biosimilars platform through CuraTeQ Biologics. Recent progress includes successful Phase 3 trials for Omalizumab, with regulatory filings planned for Q2 2026. Aurobindo also secured key partnerships, including a licensing agreement with STADA for distributing two EMA-approved biosimilars in select European territories. The pipeline remains robust with 15 products currently under development to capture a total addressable market estimated at US$ 50 billion over the next decade.
Contract Manufacturing Initiatives
Aurobindo’s biologics contract manufacturing arm, TheraNym, is scaling operations with a new greenfield facility (Unit 2). This project, involving an estimated US$ 150-175 million in capital expenditure, will house 60 kL of mammalian cell-culture capacity. The expansion strengthens the company’s collaboration with MSD and positions TheraNym to play a critical role in the global biologics supply chain by 2030.
Source: BSE
